A 2019 survey of 171 individuals who recommend medical cannabis found wide variation in training, dosing approaches, and clinical practices, with no evidence-based guidelines underpinning their advice. The study reveals a practitioner-generated “community standard” emerging in a regulatory vacuum, raising questions about patient safety and the quality of cannabis guidance available to the public.

Tens of millions of Americans now have legal access to medical cannabis, yet the clinicians and advisors guiding their use operate without standardized training, validated dosing protocols, or formal clinical guidelines. When a majority of licensed recommenders report advising cannabis as a substitute for or adjunct to prescription medications, the absence of systematic pharmacological frameworks raises real safety concerns. Understanding who these advisors are and how they practice is a prerequisite for building the guardrails the field urgently needs.

As medical cannabis legalization expanded across the United States through 2018, a growing but largely uncharacterized group of individuals began advising patients on cannabis use for therapeutic purposes. This cross-sectional survey, conducted between June and December 2018, recruited 171 self-identified cannabis recommenders through professional cannabis organizations including the American Cannabis Nurses Association, the Society of Cannabis Clinicians, and the American Academy of Cannabinoid Medicine. The sample included 144 licensed clinicians (predominantly registered nurses and physicians) and 25 unlicensed proxy advisors. The study aimed to characterize their demographics, training, practice patterns, and the emerging norms governing their recommendations in the absence of formal clinical guidelines.

Key findings revealed that while 95.5% of licensed respondents reported formal cannabis-specific education compared to 76.9% of unlicensed respondents (OR 6.3, 95% CI 1.2 to 32.3), neither group operated within validated clinical frameworks. Approximately 83% of licensed respondents had recommended cannabis as an adjunct to a prescription drug and 72% as a substitute, raising concerns about unmonitored drug interactions. Practitioners showed constituent-specific preferences for administration: vaporization was favored when THC was the therapeutic target (71.4%), while oral or sublingual routes predominated for CBD-focused recommendations (71.4%). The authors concluded that a practitioner-generated community standard is forming organically but without evidence-based underpinnings. The primary limitations include the convenience sample recruited through pro-cannabis organizations, a novel and unvalidated 255-item survey instrument, and a small unlicensed subgroup that limits the precision of between-group comparisons. The authors call for formal education standards and clinical practice guidelines.

This study captures something I have seen firsthand for years: a landscape in which well-intentioned providers are essentially building the airplane while flying it. The finding that formal education is more common among licensed providers is reassuring at a surface level, but the deeper issue is that “formal education” in this space often means weekend conferences or self-directed coursework with no standardized curriculum. When the same respondents report advising cannabis alongside or instead of prescription medications, the gap between good intentions and pharmacological rigor becomes clinically concerning.

In my own practice, I treat every cannabis recommendation as a pharmacological decision that requires the same diligence as prescribing any medication. That means reviewing the full medication list, considering CYP450 interactions, documenting rationale, and building follow-up into the care plan. The survey’s snapshot of a self-generated community standard is honestly not surprising, but it should serve as a call for clinicians who do this work to hold themselves to a higher bar than the field currently requires.

For clinicians, this study sits at an important inflection point in the research arc for cannabis medicine. It does not evaluate outcomes or validate dosing protocols; rather, it documents the current state of practice among engaged cannabis advisors at a moment when evidence-based guidelines remain essentially nonexistent. The finding that nearly three-quarters of licensed respondents have recommended cannabis as a prescription drug substitute, without standardized interaction monitoring, should prompt critical self-reflection among providers working in this space. The practitioner-derived consensus around THC vaporization versus CBD oral administration is intriguing as a hypothesis-generating observation, but it should not be mistaken for validated clinical guidance.

Pharmacologically, the adjunct and substitution patterns described here carry meaningful risk. Cannabinoids are known inhibitors of CYP3A4 and CYP2C19, with the potential to alter serum levels of common medications including warfarin, clobazam, and certain antidepressants. Clinicians recommending cannabis alongside or in place of prescription drugs should be reviewing interaction databases, counseling patients on dose-timing separation, and scheduling follow-up to reassess therapeutic and adverse effects. One concrete recommendation: any provider recommending medical cannabis should maintain a structured medication reconciliation process identical to the one used for any new prescription, documenting the indication, target dose range, expected timeline, and monitoring plan.